Proficio Capital Partners LLC Invests $1.10 Million in Abbott Laboratories $ABT

Proficio Capital Partners LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 12,158 shares of the healthcare product maker’s stock, valued at approximately $1,103,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares in the last quarter. United Bank lifted its position in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC lifted its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after acquiring an additional 292,547 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ABT shares. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 6th. TD Cowen increased their price target on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Price Performance

NYSE ABT opened at $110.52 on Thursday. The company has a market cap of $191.24 billion, a price-to-earnings ratio of 35.77, a PEG ratio of 2.02 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock’s fifty day moving average price is $103.83 and its 200 day moving average price is $100.09. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.